MAR002

Phase 2Small molecule

MMarea Therapeutics

MAR002 is one of 6 small molecule programs targeting Acromegaly. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AcromegalyRecruiting

AcromegalyPhase 2

Recruiting

Competition

Competitive Landscape

11 competitors in Acromegaly

#DrugCompanyPhaseTrials

Sandostatin

Sun Pharma

Approved

7 2

Lanreotide Acetate

AAlbireo, an Ipsen Company

Approved

5 3

Dostinex

MAR002

1 5

Genotropin

Pfizer

Preclinical

1 6

Sandostatin

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Acromegaly

NCT07641179

Clinical

Trials by Indication[1]

Acromegaly1 trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR002 in Participants With Acromegaly (TROUGH-2)

Recruiting·MMarea Therapeutics·Phase 2·NCT07641179·72 enrolled

Unspecified1 trial

Study of MAR002 in Healthy Men

Recruiting·MMarea Therapeutics·Phase 1·NCT07195175·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MAR002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MAR002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MAR002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Marea Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMarea Therapeutics

MAR002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Acromegaly1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News